AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25086124 — intervention group
Group type: EXPERIMENTAL
Intervention: Porocoat coating
Number of subjects: 20
Study 25086124 — intervention group
Group type: EXPERIMENTAL
Intervention: DuoFix hydroxyapatite (HA) coating
Number of subjects: 20
Study 22712503 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) with medical treatment as usual, 8 sessions
Number of subjects: 30
Study 22712503 — intervention group
Group type: COMPARATOR
Intervention: Control group received only medical treatment as usual
Number of subjects: 30
Study 20737295 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual aids (icon arrays, horizontal bars, vertical bars, or pies)
Number of subjects: 987
Study 20737295 — intervention group
Group type: EXPERIMENTAL
Intervention: Icon arrays
Number of subjects: 987
Study 20737295 — intervention group
Group type: COMPARATOR
Intervention: Framing effects (positive vs negative risk presentation)
Number of subjects: 987
Study 18301120 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (e.g., olanzapine, risperidone, quetiapine)
Number of subjects: 0
Study 18301120 — intervention group
Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors and serotonin‐noradrenaline reuptake inhibitors
Number of subjects: 0
Study 15492764 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR and behavioral counseling
Number of subjects: 0
Study 12592551 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg of methylprednisolone intravenously at the end of the operation and 12 and 24 hours later (group II)
Number of subjects: 236
Study 12592551 — intervention group
Group type: COMPARATOR
Intervention: Control group (group I)
Number of subjects: 236
Study 10560385 — intervention group
Group type: EXPERIMENTAL
Intervention: HAI chemotherapy (12 g of 5‐FU administered in 6 weeks)
Number of subjects: 58
Study 10560385 — intervention group
Group type: COMPARATOR
Intervention: Control group (randomly selected)
Number of subjects: 58
Study 10560385 — intervention group
Group type: EXPERIMENTAL
Intervention: HAI chemotherapy (1,000-1,500 mg/w of 5‐FU)
Number of subjects: 58
Study 10560385 — intervention group
Group type: COMPARATOR
Intervention: Transarterial embolization (TAE) group
Number of subjects: 58
Study 7472904 — intervention group
Group type: EXPERIMENTAL
Intervention: fermented whey-adapted infant formula containing viable bifidobacteria (10^6/g of powder)
Number of subjects: 20
Study 7472904 — intervention group
Group type: COMPARATOR
Intervention: nonacidified, low-phosphate infant formula
Number of subjects: 20
Study 7472904 — intervention group
Group type: COMPARATOR
Intervention: breast-fed infants
Number of subjects: 20
Study 2337034 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 60 mg/kg/day for 7 days starting on the third postoperative day (group 1, 32 patients)
Number of subjects: 74
Study 2337034 — intervention group
Group type: COMPARATOR
Intervention: No aspirin (group 2, 42 patients)
Number of subjects: 74
Study 2337034 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 60 mg/kg/day for 7 days
Number of subjects: 74
Study 2337034 — intervention group
Group type: COMPARATOR
Intervention: No aspirin
Number of subjects: 74
Study 2337034 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin prophylaxis
Number of subjects: 74
Study 447949 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 45
Study 447949 — intervention group
Group type: EXPERIMENTAL
Intervention: Azo dyes (tartrazine, sunset yellow, amaranth, ponceau)
Number of subjects: 45
Study 447949 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-azo dyes (erythrosine, brilliant blue, indigotin)
Number of subjects: 45
Study 447949 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium benzoate (NaB) and parahydroxybenzoic acid (OHBA)
Number of subjects: 45
Study 447949 — intervention group
Group type: EXPERIMENTAL
Intervention: Butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT)
Number of subjects: 45
Study 31809323 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel trial designs (including cluster designs, real-time automated enrollment, practitioner-preference approaches)
Number of subjects: 0
Study 31809323 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive designs
Number of subjects: 0
Study 31809323 — intervention group
Group type: EXPERIMENTAL
Intervention: Embedding randomized trials within registries
Number of subjects: 0
Study 30725226 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 0
Study 30725226 — intervention group
Group type: COMPARATOR
Intervention: Active Monitoring (AM)
Number of subjects: 0
Study 28952201 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant plus palonosetron (administered with dexamethasone)
Number of subjects: 78
Study 28952201 — intervention group
Group type: COMPARATOR
Intervention: Palonosetron plus dexamethasone (control group)
Number of subjects: 78
Study 25546165 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal (900 mg) under fasting condition
Number of subjects: 12
Study 25546165 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal (900 mg) under fed condition (after a high-fat meal)
Number of subjects: 12
Study 22834565 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) therapy
Number of subjects: 201
Study 21161171 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia (three 30-min sessions per week for 4 weeks using a 433.92 MHz microwave generator)
Number of subjects: 63
Study 21161171 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (machine not turned on)
Number of subjects: 63
Study 19278806 — intervention group
Group type: EXPERIMENTAL
Intervention: Sophrology during the first 30 min of NIV (S group)
Number of subjects: 30
Study 19278806 — intervention group
Group type: COMPARATOR
Intervention: Standard care during 30 min (T group)
Number of subjects: 30
Study 17188845 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAN 2.1
Number of subjects: 0
Study 15075653 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin (BoTx) injection, 8 to 100 units injected twice, a month apart at the esophagogastric junction.
Number of subjects: 80
Study 15075653 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic myotomy (anterior partial (Dor) or Nissen fundoplication).
Number of subjects: 80
Study 15075653 — intervention group
Group type: COMPARATOR
Intervention: Both interventions (BoTx and myotomy).
Number of subjects: 80
Study 11309017 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (300 microg p.o.) 90 min prior to surgery
Number of subjects: 40
Study 11309017 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study 9329702 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine with estrogen replacement therapy (ERT)
Number of subjects: 318
Study 9329702 — intervention group
Group type: COMPARATOR
Intervention: Tacrine without estrogen replacement therapy (ERT)
Number of subjects: 318
Study 9329702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study 7957513 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms nebulised OTB
Number of subjects: 12
Study 7957513 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 micrograms nebulised OTB
Number of subjects: 12
Study 7957513 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 micrograms nebulised OTB
Number of subjects: 12
Study 7957513 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 micrograms nebulised OTB
Number of subjects: 12
Study 3299178 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam 0.25 mg administered three times daily from cycle day 20 until the second day of menstruation, tapered by one tablet per day thereafter.
Number of subjects: 0
Study 3299178 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo administered three times daily from cycle day 20 until the second day of menstruation, tapered by one tablet per day thereafter.
Number of subjects: 0
Study 29556706 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative glove changing
Number of subjects: 553
Study 29556706 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 553
Study 27169838 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange maizemeal (200 g, 6 days/week for 6 months)
Number of subjects: 1024
Study 27169838 — intervention group
Group type: COMPARATOR
Intervention: White maizemeal (200 g, 6 days/week for 6 months)
Number of subjects: 1024
Study 27169838 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention group
Number of subjects: 1024
Study 25035292 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg intravenous every 3-4 weeks for six doses, then every 3 months for eight doses, followed by every 6 months for five doses, for a total of 5 years)
Number of subjects: 3360
Study 25035292 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 3360
Study 23666772 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance-based behavioral treatment (ABT)
Number of subjects: 128
Study 23666772 — intervention group
Group type: COMPARATOR
Intervention: Standard behavioral treatment (SBT)
Number of subjects: 128
Study 23666772 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT from experts
Number of subjects: 128
Study 23666772 — intervention group
Group type: COMPARATOR
Intervention: SBT from experts
Number of subjects: 128
Study 23666772 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT for participants with greater baseline depression
Number of subjects: 128
Study 23666772 — intervention group
Group type: COMPARATOR
Intervention: SBT for participants with greater baseline depression
Number of subjects: 128
Study 23666772 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT for emotional eating
Number of subjects: 128
Study 23666772 — intervention group
Group type: COMPARATOR
Intervention: SBT for emotional eating
Number of subjects: 128
Study 23666772 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT for disinhibition
Number of subjects: 128
Study 23666772 — intervention group
Group type: COMPARATOR
Intervention: SBT for disinhibition
Number of subjects: 128
Study 23666772 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT for responsivity to food cues
Number of subjects: 128
Study 23666772 — intervention group
Group type: COMPARATOR
Intervention: SBT for responsivity to food cues
Number of subjects: 128
Study 20613459 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 cell count above 200 cells/microl
Number of subjects: 812
Study 20613459 — intervention group
Group type: COMPARATOR
Intervention: CD4 cell count of 200 cells/microl or less
Number of subjects: 812
Study 20613459 — intervention group
Group type: COMPARATOR
Intervention: CD4 cell count of 200 cells/microl or less or WHO IV condition
Number of subjects: 812
Study 20613459 — intervention group
Group type: COMPARATOR
Intervention: Both CD4 cell count of 200 cells/microl or less and WHO IV condition
Number of subjects: 812
Study 20613459 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiating ART at less than 200 cells/microl
Number of subjects: 812
Study 18843876 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable rigid dressing (RRD)
Number of subjects: 26
Study 18843876 — intervention group
Group type: COMPARATOR
Intervention: Elastic bandage (EB)
Number of subjects: 26
Study 16875764 — intervention group
Group type: EXPERIMENTAL
Intervention: Single incision method
Number of subjects: 65
Study 16875764 — intervention group
Group type: COMPARATOR
Intervention: Double incision method
Number of subjects: 65
Study 12804681 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) for 3 weeks
Number of subjects: 15
Study 10689845 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil infusion
Number of subjects: 300
Study 10689845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 8824004 — intervention group
Group type: EXPERIMENTAL
Intervention: MSQOL (migraine-specific quality-of-life measure)
Number of subjects: 0
Study 8824004 — intervention group
Group type: EXPERIMENTAL
Intervention: MSQOL
Number of subjects: 0
Study 1482152 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP-SMX (160:800 mg twice daily for six doses)
Number of subjects: 190
Study 1482152 — intervention group
Group type: EXPERIMENTAL
Intervention: Single large dose of TMP-SMX (320:1,600 mg)
Number of subjects: 190
Study 1482152 — intervention group
Group type: EXPERIMENTAL
Intervention: Large loading dose (320:1,600 mg) followed by standard doses (160:800 mg twice daily for five doses)
Number of subjects: 190
Study 1482152 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide (4-mg loading dose; 2 mg after each loose stool, not to exceed 16 mg/day for 3 days)
Number of subjects: 190
Study 6541200 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc as an adjunct to dapsone
Number of subjects: 15
Study 6541200 — intervention group
Group type: COMPARATOR
Intervention: Dapsone alone (Control)
Number of subjects: 15
Study 30884679 — intervention group
Group type: EXPERIMENTAL
Intervention: Hempseed oil (HSO) 3g/day providing 1.4g of linoleic acid (LA) and 0.7g of alpha-linolenic acid (ALA)
Number of subjects: 36
Study 30884679 — intervention group
Group type: COMPARATOR
Intervention: Control group (specific dietary guidelines)
Number of subjects: 36
Study 30556410 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoventricular patch
Number of subjects: 117
Study 30556410 — intervention group
Group type: COMPARATOR
Intervention: Linear suture
Number of subjects: 117
Study 28000468 — intervention group
Group type: EXPERIMENTAL
Intervention: No sweetened beverages permitted (only plain water, tea or coffee without sugar)
Number of subjects: 148
Study 28000468 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of beverages with non-caloric sweeteners allowed
Number of subjects: 148
Study 28000468 — intervention group
Group type: COMPARATOR
Intervention: No restriction of sweetened beverages imposed
Number of subjects: 148
Study 24794170 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative quiz-based teaching strategy
Number of subjects: 40
Study 24794170 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching strategy
Number of subjects: 40
Study 22124998 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg domperidone
Number of subjects: 13
Study 22124998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 19555938 — intervention group
Group type: EXPERIMENTAL
Intervention: Water infusion in lieu of air insufflation
Number of subjects: 0
Study 19555938 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 0
Study 17230049 — intervention group
Group type: EXPERIMENTAL
Intervention: Volition group therapy in addition to standard cognitive behavioral therapy (VG)
Number of subjects: 242
Study 17230049 — intervention group
Group type: COMPARATOR
Intervention: Standard cognitive behavioral therapy (SG)
Number of subjects: 242
Study 15100505 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of 99mTc-tetrofosmin
Number of subjects: 14
Study 15100505 — intervention group
Group type: COMPARATOR
Intervention: Intravenous injection of 99mTc-tetrofosmin
Number of subjects: 14
Study 11581449 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 1 to 2 ppm (low-dose group)
Number of subjects: 36
Study 11581449 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 10 to 20 ppm (high-dose group)
Number of subjects: 36
Study 11581449 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of iNO after initial treatment
Number of subjects: 36
Study 11581449 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study 10923477 — intervention group
Group type: EXPERIMENTAL
Intervention: H2 strain vaccine (10^7.0 TCID50)
Number of subjects: 135340
Study 10923477 — intervention group
Group type: EXPERIMENTAL
Intervention: LA-1 strain vaccine (10^6.75 TCID50)
Number of subjects: 135340
Study 10923477 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaccination)
Number of subjects: 135340
Study 10923477 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined efficacy of H2 and LA-1 vaccines
Number of subjects: 135340
Study 7986415 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS education program
Number of subjects: 2026
Study 2567140 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (10 minutes pedaling on a fixed bicycle with ergometer)
Number of subjects: 36
Study 2567140 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (CL)
Number of subjects: 36
Study 2567140 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (GU)
Number of subjects: 36
Study 29791895 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial ingestion of esomeprazole 40 mg
Number of subjects: 32
Study 29791895 — intervention group
Group type: COMPARATOR
Intervention: Preprandial ingestion of esomeprazole 40 mg
Number of subjects: 32
Study 26631687 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory Stimulation Environment (MSSE)
Number of subjects: 32
Study 26631687 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity sessions
Number of subjects: 32
Study 26631687 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 25636696 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg once daily for 5 days + HCTZ 25 mg once daily for 4 days
Number of subjects: 22
Study 25636696 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg once daily for 5 days + TOR 5 mg once daily for 4 days
Number of subjects: 22
Study 25636696 — intervention group
Group type: COMPARATOR
Intervention: HCTZ 25 mg once daily
Number of subjects: 22
Study 25636696 — intervention group
Group type: COMPARATOR
Intervention: TOR 5 mg once daily
Number of subjects: 22
Study 23916935 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release (ER) niacin 1,500 to 2,000 mg
Number of subjects: 3414
Study 23916935 — intervention group
Group type: COMPARATOR
Intervention: Minimal immediate-release niacin (≤ 150 mg) as placebo
Number of subjects: 3414
Study 21112424 — intervention group
Group type: EXPERIMENTAL
Intervention: Active resistive exercise with complex decongestive physiotherapy
Number of subjects: 40
Study 21112424 — intervention group
Group type: COMPARATOR
Intervention: Nonactive resistive exercise (only complex decongestive physiotherapy)
Number of subjects: 40
Study 18945506 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus LC705 and Propionibacterium freudenreichii ssp. shermanii JS (2x10(10) CFU of each strain daily)
Number of subjects: 38
Study 18945506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 16318643 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-Control Ventilation (PCV)
Number of subjects: 14
Study 16318643 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-Regulated Volume-Control (PRVC)
Number of subjects: 14
Study 16318643 — intervention group
Group type: COMPARATOR
Intervention: Volume-Control Ventilation (VCV)
Number of subjects: 14
Study 16318643 — intervention group
Group type: EXPERIMENTAL
Intervention: All modes (PCV, PRVC, VCV)
Number of subjects: 14
Study 14560232 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 85
Study 14560232 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with chronic venous disease
Number of subjects: 85
Study 14560232 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoropopliteal veins
Number of subjects: 85
Study 14560232 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing position
Number of subjects: 85
Study 14560232 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 85
Study 14560232 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak vein velocity
Number of subjects: 85
Study 10506617 — intervention group
Group type: EXPERIMENTAL
Intervention: CT + RT (mitomycin 6 mg/m2, ifosfamide 3 g/m2, cisplatin 50 mg/m2 every 21 days for up to four cycles followed by radical radiotherapy)
Number of subjects: 797
Study 10506617 — intervention group
Group type: EXPERIMENTAL
Intervention: CT + PC (mitomycin 6 mg/m2, ifosfamide 3 g/m2, cisplatin 50 mg/m2 plus palliative care)
Number of subjects: 797
Study 10506617 — intervention group
Group type: COMPARATOR
Intervention: RT alone (radiotherapy only)
Number of subjects: 797
Study 10506617 — intervention group
Group type: COMPARATOR
Intervention: PC alone (palliative care only)
Number of subjects: 797
Study 10506617 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT)
Number of subjects: 797
Study 10506617 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (RT or PC)
Number of subjects: 797
Study 8754368 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to mercury vapours
Number of subjects: 0
Study 8754368 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exposed subjects)
Number of subjects: 0
Study 1862570 — intervention group
Group type: EXPERIMENTAL
Intervention: Observer evaluations of ascites
Number of subjects: 8
Study 1862570 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-observer evaluations
Number of subjects: 8
Study 1862570 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective certainty of correctness
Number of subjects: 8
Study 1862570 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic investigation
Number of subjects: 8
Study 6138939 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 0
Study 6138939 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study 31775534 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality salience (n=290)
Number of subjects: 986
Study 31775534 — intervention group
Group type: COMPARATOR
Intervention: Control (n=302)
Number of subjects: 986
Study 31775534 — intervention group
Group type: EXPERIMENTAL
Intervention: Generativity and meaning in life, self-esteem, and social support
Number of subjects: 986
Study 31329221 — intervention group
Group type: EXPERIMENTAL
Intervention: Documented myocardial ischemia
Number of subjects: 611
Study 31329221 — intervention group
Group type: COMPARATOR
Intervention: No documented ischemia
Number of subjects: 611
Study 31329221 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic evaluation after 10 years
Number of subjects: 611
Study 27631118 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation
Number of subjects: 196
Study 27631118 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 196